Eloxx Pharmaceuticals and AlloVir Compared in Head-to-Head Analysis

Researchers examine key metrics like volatility, institutional ownership, and valuation between the two biotech firms.

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

A new analysis compares the key financial and operational metrics of Eloxx Pharmaceuticals and AlloVir, two clinical-stage biotech companies. The data shows AlloVir has significantly lower stock price volatility and stronger institutional ownership compared to Eloxx Pharmaceuticals. However, Eloxx Pharmaceuticals appears to have an edge in terms of valuation and profitability ratios.

Why it matters

This head-to-head comparison provides investors with valuable insights to assess the relative strengths and weaknesses of these two biotech firms as potential investment opportunities. The analysis highlights important factors like risk, management ownership, and financial performance that can inform investment decisions in the volatile pharmaceutical sector.

The details

The analysis found that AlloVir has a beta of 0.63, indicating its stock price is 37% less volatile than the overall S&P 500 market. In contrast, Eloxx Pharmaceuticals has an extremely high beta of -1721.71, meaning its stock price is over 172,000% more volatile than the broader market. Additionally, 66.1% of AlloVir's shares are owned by institutional investors compared to just 2.9% for Eloxx Pharmaceuticals. Insiders also own a larger stake in AlloVir at 32.1% versus 20.2% for Eloxx. In terms of valuation, AlloVir is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating it is the more affordable of the two stocks. However, Eloxx Pharmaceuticals has stronger profit margins, return on equity, and return on assets.

  • The analysis was published on March 10, 2026.

The players

AlloVir

An American biotechnology company that develops off-the-shelf virus-specific T-cell therapies to prevent and treat severe viral diseases.

Eloxx Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing treatments for rare and ultra-rare premature stop codon diseases.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the trade-offs investors must weigh when considering Eloxx Pharmaceuticals and AlloVir as potential investments. AlloVir appears to offer lower risk and stronger institutional backing, while Eloxx Pharmaceuticals shows better profitability metrics. Ultimately, investors will need to assess which factors are most important to their individual investment goals and risk tolerance.